ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Oramed Pharmaceuticals Granted Approval To Conduct Phase 2A Trials Of Its Oral Insulin Capsule
Oramed Pharmaceuticals Inc. has been granted approval by the Institutional Review
Board (IRB) committee of Hadassah Medical Center in Jerusalem to
conduct a Phase 2A study of its oral insulin on diabetic volunteers.
This Phase 2A study is designed to evaluate the safety and efficacy
of Oramed's oral insulin capsule on Type II diabetic volunteers. This
study is slated to begin in the second quarter of 2008. The trials
are expected to last several months.
"Oramed's oral insulin aims to revolutionize the current methods of
treating diabetes," said Nadav Kidron, CEO of Oramed Pharmaceuticals.
"An effective oral insulin capsule would make insulin an earlier form
of treatment for diabetes patients, thereby allowing them to better
control and balance their disease, leading to a healthier overall
condition."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is an Israeli-based company focused on the
development of oral delivery solutions based on proprietary
technology. Diabetes is one of the most rapidly growing diseases in
the world and is one that requires constant and often unpleasant
monitoring and drug therapy regimens. Oramed is currently developing
an orally ingestible insulin capsule for the treatment of diabetes.
The company is also pursuing the development of oral delivery
solutions for other drugs and vaccines.
For more information please visit our website at: http://www.oramed.com.
Forward-looking statements
Some of the statements contained in this press release are forward-
looking statements which involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking statements,
including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development
programs; difficulties or delays in obtaining regulatory approval for
our product candidates; competition from other pharmaceutical or
biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings
with the Securities and Exchange commission for a comprehensive list
of risk factors that could cause actual results, performance or
achievements of the company to differ materially from those expressed
or implied in such forward looking statements. The company undertakes
no obligation to update or revise any forward-looking statements.
http://www.oramed.com
Oramed produse farmaceutice a acordat aprobarea de a efectua studii clinice de Fazã 2a de la insulinã oralã capsulã - Oramed Pharmaceuticals Granted Approval To Conduct Phase 2A Trials Of Its Oral Insulin Capsule - articole medicale engleza - startsanatate